Cited 0 times in Scipus Cited Count

A novel biguanide (IM1761065) inhibits bioenergetics of glioblastoma tumorspheres

DC Field Value Language
dc.contributor.authorRoh, TH-
dc.contributor.authorLee, JH-
dc.contributor.authorKim, SJ-
dc.contributor.authorShim, JK-
dc.contributor.authorPark, J-
dc.contributor.authorYoon, SJ-
dc.contributor.authorTeo, WY-
dc.contributor.authorKim, SH-
dc.contributor.authorChang, JH-
dc.contributor.authorKang, SG-
dc.date.accessioned2023-02-27T07:12:43Z-
dc.date.available2023-02-27T07:12:43Z-
dc.date.issued2022-
dc.identifier.issn0167-594X-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/24849-
dc.description.abstractPURPOSE: Glioblastoma (GBM) is a rapidly growing tumor in the central nervous system with altered metabolism. Depleting the bioenergetics of tumors with biguanides have been suggested as an effective therapeutic approach for treating GBMs. The purpose of this study was to determine the effects of IM1761065, a novel biguanide with improved pharmacokinetics, on GBM-tumorspheres (TSs). METHODS: The biological activities of IM1761065 on GBM-TSs, including their effects on viability, ATP levels, cell cycle, stemness, invasive properties, and transcriptomes were examined. The in vivo efficacy of IM1761065 was tested in a mouse orthotopic xenograft model. RESULTS: IM1761065 decreased the viability and ATP levels of GBM-TSs in a dose-dependent manner, and reduced basal and spare respiratory capacity in patient-derived GBM-TS, as measured by the oxygen consumption rate. Sphere formation, expression of stemness-related proteins, and invasive capacity of GBM-TSs were also significantly suppressed by IM1761065. A gene-ontology comparison of IM1761065-treated groups showed that the expression levels of stemness-related, epithelial mesenchymal transition-related, and mitochondrial complex I genes were also significantly downregulated by IM1761065. An orthotopic xenograft mouse model showed decreased bioluminescence in IM1761065-treated cell-injected mice at 5 weeks. IM1761065-treated group showed longer survival than the control group (P = 0.0289, log-rank test). CONCLUSION: IM1761065 is a potent inhibitor of oxidative phosphorylation. The inhibitory effect of IM1761065 on the bioenergetics of GBM-TS suggests that this novel compound could be used as a new drug for the treatment of GBM.-
dc.language.isoen-
dc.subject.MESHAdenosine Triphosphate-
dc.subject.MESHAnimals-
dc.subject.MESHBiguanides-
dc.subject.MESHBrain Neoplasms-
dc.subject.MESHCell Line, Tumor-
dc.subject.MESHEnergy Metabolism-
dc.subject.MESHGlioblastoma-
dc.subject.MESHHumans-
dc.subject.MESHMice-
dc.subject.MESHXenograft Model Antitumor Assays-
dc.titleA novel biguanide (IM1761065) inhibits bioenergetics of glioblastoma tumorspheres-
dc.typeArticle-
dc.identifier.pmid34811601-
dc.subject.keywordBiguanide-
dc.subject.keywordBioenergetics-
dc.subject.keywordGlioblastoma-
dc.subject.keywordIM1761065-
dc.subject.keywordTumorsphere-
dc.contributor.affiliatedAuthorRoh, TH-
dc.type.localJournal Papers-
dc.identifier.doi10.1007/s11060-021-03903-7-
dc.citation.titleJournal of neuro-oncology-
dc.citation.volume156-
dc.citation.number1-
dc.citation.date2022-
dc.citation.startPage139-
dc.citation.endPage151-
dc.identifier.bibliographicCitationJournal of neuro-oncology, 156(1). : 139-151, 2022-
dc.embargo.liftdate9999-12-31-
dc.embargo.terms9999-12-31-
dc.identifier.eissn1573-7373-
dc.relation.journalidJ00167594X-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Neurosurgery
Files in This Item:
There are no files associated with this item.

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse